Despite doubts, drugmakers double down on anti-amyloid approach

4 March 2022

Setting aside trouble gaining market access for the newly-approved Aduhelm (aducanumab), Eisai (TYO: 4523) and Biogen (Nasdaq: BIIB) continue to pursue early registration of their next-generation Alzheimer’s med.

Based on discussions with Japan’s Ministry of Health, Labor and Welfare (MHLW), Eisai has been granted permission to use the “prior assessment consultation” process for lecanemab, with the goal of shortening the review period.

The additional data of the application package will now be submitted, with primary endpoint data from the key Clarity AD study expected later in 2022.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK